ImmunoPrecise Antibodies Balance Sheet Health
Financial Health criteria checks 2/6
ImmunoPrecise Antibodies has a total shareholder equity of CA$32.9M and total debt of CA$2.6M, which brings its debt-to-equity ratio to 7.9%. Its total assets and total liabilities are CA$59.3M and CA$26.4M respectively.
Key information
7.9%
Debt to equity ratio
CA$2.60m
Debt
| Interest coverage ratio | n/a |
| Cash | CA$3.91m |
| Equity | CA$32.85m |
| Total liabilities | CA$26.45m |
| Total assets | CA$59.30m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: TQB's short term assets (CA$11.0M) do not cover its short term liabilities (CA$11.2M).
Long Term Liabilities: TQB's short term assets (CA$11.0M) do not cover its long term liabilities (CA$15.3M).
Debt to Equity History and Analysis
Debt Level: TQB has more cash than its total debt.
Reducing Debt: TQB's debt to equity ratio has reduced from 18.4% to 7.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TQB has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: TQB has less than a year of cash runway if free cash flow continues to reduce at historical rates of 27% each year